Connor, Clark & Lunn Investment Management Ltd. Ligand Pharmaceuticals Inc Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $18.8 Billion
- Q3 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 26,963 shares of LGND stock, worth $3.31 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
26,963
Previous 17,296
55.89%
Holding current value
$3.31 Million
Previous $1.46 Million
85.31%
% of portfolio
0.01%
Previous 0.01%
Shares
8 transactions
Others Institutions Holding LGND
# of Institutions
257Shares Held
18.2MCall Options Held
26.8KPut Options Held
9.3K-
Black Rock Inc. New York, NY2.87MShares$352 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.97MShares$242 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X01.01MShares$124 Million0.05% of portfolio
-
Macquarie Group LTD Australia, C3887KShares$109 Million0.1% of portfolio
-
State Street Corp Boston, MA707KShares$86.8 Million0.0% of portfolio
About LIGAND PHARMACEUTICALS INC
- Ticker LGND
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 16,882,800
- Market Cap $2.07B
- Description
- Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...